Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis

BACKGROUND: KRAS mutation status in codons 12 and 13 is recognized as a predictive factor for resistance to anti-EGFR monoclonal antibodies. Despite having a wild type KRAS (wt-KRAS), not all patients with wt-KRAS respond to anti-EGFR antibody treatment. Additional mechanisms of resistance may activ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Formato: Artigo
Lenguaje:Inglês
Publicado: Versita, Warsaw 2011
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3423757/
https://ncbi.nlm.nih.gov/pubmed/22933967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/v10019-011-0039-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares